Education
About Us
Working with TipRanks
Follow Us
CANC - ETF AI Analysis
Top Page
Tema Oncology ETF (CANC)
Rating:62Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid returns so far this year, reflecting strength in its holdings.
Focused Health Care Exposure
Nearly all assets are invested in the health care sector, which benefits from long-term growth trends in oncology.
High-Performing Holdings
Several top holdings, such as Genmab and BridgeBio Pharma, have shown strong gains, contributing positively to the fund.
Negative Factors
Sector Concentration Risk
The ETF is heavily concentrated in health care, making it vulnerable to sector-specific downturns.
Geographic Overweight in the U.S.
The fund has significant exposure to U.S. companies, limiting diversification across global markets.
Higher Expense Ratio
The ETF charges a relatively high expense ratio compared to broader market funds, which can reduce net returns over time.
CANC vs. SPDR S&P 500 ETF (SPY)
AUM135.57M
RegionGlobal
Expense Ratio0.75%
Beta0.81
IssuerTema
Inception DateAug 15, 2023
Dividend Yield0.05%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume59,808
30 Day Avg. Volume30,225
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
47.48Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering57
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CANC Summary
The Tema Oncology ETF (Ticker: CANC) is an investment fund focused on companies in the health care sector, specifically those involved in cancer research and treatment. It includes well-known names like Eli Lilly & Co and Roche Holding, along with other firms developing innovative therapies and technologies in oncology. This ETF is designed for investors who want to support advancements in cancer care while potentially benefiting from the growth of this critical field. However, new investors should be aware that the ETF is heavily concentrated in health care, meaning its performance can be significantly affected by changes in the industry or regulatory challenges.
How much will it cost me?The Tema Oncology ETF has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the health care sector that requires expert research and selection of companies.
What would affect this ETF?The Tema Oncology ETF could benefit from advancements in cancer research and increased global demand for innovative treatments, as well as strong performance from top holdings like Eli Lilly and Roche, which are leaders in oncology. However, it may face challenges from regulatory hurdles, high development costs in the biotech sector, and potential economic downturns that could impact funding for healthcare innovation.
CANC Top 10 Holdings
The Tema Oncology ETF is laser-focused on the health care sector, with a global mix of biotech and pharmaceutical heavyweights driving its performance. Rising stars like BridgeBio Pharma and Cogent Biosciences are leading the charge, fueled by strong trial results and technical momentum, while Revolution Medicines is lagging due to financial challenges and bearish trends. Eli Lilly and AstraZeneca provide steady support, though valuation concerns temper their impact. With nearly all its holdings in health care, this fund is a concentrated bet on the future of cancer treatment innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Revolution Medicines | 7.37% | $10.03M | $23.43B | 201.15% | 52 Neutral | |
| Eli Lilly & Co | 4.64% | $6.31M | $1.01T | 43.73% | 72 Outperform | |
| Novartis AG | 4.63% | $6.30M | CHF220.89B | 28.13% | 80 Outperform | |
| BridgeBio Pharma | 4.42% | $6.01M | $15.01B | 122.19% | 59 Neutral | |
| AstraZeneca | 4.34% | $5.91M | £222.43B | 34.73% | 80 Outperform | |
| Roche Holding | 4.03% | $5.48M | $343.86B | 47.84% | 74 Outperform | |
| Merck & Company | 3.86% | $5.25M | $275.53B | 10.91% | 80 Outperform | |
| Genmab | 3.76% | $5.11M | $21.59B | 67.42% | 76 Outperform | |
| Bristol-Myers Squibb | 3.45% | $4.69M | $116.08B | 1.98% | 78 Outperform | |
| Cogent Biosciences | 3.12% | $4.25M | $5.75B | 334.48% | 37 Underperform |
CANC Technical Analysis
Positive
―
Price Trends
34.35
Positive
31.43
Positive
28.10
Positive
Market Momentum
0.59
Negative
65.53
Neutral
87.69
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CANC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 35.29, equal to the 50-day MA of 34.35, and equal to the 200-day MA of 28.10, indicating a bullish trend. The MACD of 0.59 indicates Negative momentum. The RSI at 65.53 is Neutral, neither overbought nor oversold. The STOCH value of 87.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CANC.
CANC Peer Comparison
Comparison Results
Performance Comparison
CANC
Tema Oncology ETF
37.08
12.60
51.47%
EIPI
FT Energy Income Partners Enhanced Income ETF
―
―
―
AVRE
Avantis Real Estate ETF
―
―
―
ARKX
ARK Space Exploration & Innovation ETF
―
―
―
VGSR
Vert Global Sustainable Real Estate ETF
―
―
―
BKGI
BNY Mellon Global Infrastructure Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents